Selective eradication of cancer displaying hyperactive Akt by exploiting the metabolic consequences of Akt activation

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Akt activation in human cancers contributes to chemoresistance.
• Pan-Akt inhibition can lead to adverse effects.
• Prostate cancer with hyperactive Akt exhibits altered metabolism and high reactive oxygen species (ROS) levels.

Purpose of the Study:

• To develop a therapeutic strategy for chemoresistant prostate cancer with hyperactive Akt.
• To exploit Akt-mediated metabolic alterations for selective cancer cell eradication.
• To investigate the role of ROS and glucose metabolism in PTEN-deficient prostate tumors.

Main Methods:

• Combining a ROS inducer with rapamycin in PTEN-deficient prostate tumor mouse models.
• Evaluating the effects of antioxidant exposure on tumor progression.
• Assessing the impact of Hexokinase 2 (HK2) deficiency on tumor development.

Main Results:

• The combination therapy of a ROS inducer and rapamycin led to tumor regression and increased survival in mouse models.
• Antioxidant exposure exacerbated prostate tumor progression.
• HK2 deficiency significantly inhibited tumor development and extended lifespan in Pten-deficient prostate cancer models.

Conclusions:

• Targeting ROS-induced cell death and inhibiting glucose metabolism are effective strategies against chemoresistant prostate cancer.
• Modulating metabolic pathways offers a novel approach to overcome Akt-driven chemoresistance.
• HK2 is a critical factor in Akt-driven prostate cancer progression.